Nuvation Bio completed its business combination with Panacea Acquisition, a blank-check company sponsored by EcoR1 Capital. Shares of the combined company begin trading today on the NYSE under NUVB.
Nuvation is a biopharmaceutical company developing therapeutic drugs for treating cancer.
Panacea shareholders approved the $644 million merger yesterday. Read more.
